Hikal incubates animal health, personal care units for growth

Active ingredients maker Hikal Ltd. is incubating animal health and personal care businesses under a 2030 strategy focused on diversification and capital efficiency. It aims for over ₹400 crore in animal health revenue and above ₹200 crore from personal care by FY30, with commercial production begun at Panoli. Pharma contributes 60% of revenue and crop protection 40%, said Sameer Hiremath. FY26 revenue was ₹1,713 crore with EBITDA of ₹232.8 crore, a 13.6% margin. IiAS backed Hiremath's appointment ahead of the September 23 AGM.

Written by AI from The Hindu — Business · not yet reviewed by an editor · Published 22 Sept 2026, 3:38 am IST

Source

The Hindu — Business · read the original report ↗

#hikal#animal health#personal care#pharma#diversification#iias

Desk check · compared with the source

What the desk checked (4)

Hikal targets over ₹400 crore revenue from animal health and above ₹200 crore from personal care by FY30. — Figures appear in source, attributed to company plans stated by its executives.
Revenue currently splits 60% pharma and 40% crop protection. — Directly quoted to Vice-Chairman and MD Sameer Hiremath.
FY26 revenue of ₹1,713 crore and EBITDA of ₹232.8 crore at 13.6% margin, with 14-16% growth expected in FY27. — Figures stated in source as company-reported; not independently verified here.
IiAS recommends shareholders approve Sameer Hiremath as Chairperson and MD for five years from October 1, 2026, ahead of the September 23 AGM. — Attributed to proxy advisory firm IiAS in the source.

Written by AI from The Hindu — Business · not yet reviewed by an editor · How we use AI · Report an error

Analysts’ view opinion

AI Economic Analyst

Stripped to its economics, Hikal's plan is about widening its revenue base without building a new manufacturing platform — reusing existing assets, regulatory systems and multinational customer relationships. Against FY26 revenue of ₹1,713 crore, the FY30 targets of over ₹400 crore from animal health and ₹200 crore from personal care would make the new verticals a meaningful slice, shifting today's 60% pharma and roughly 40% crop protection mix. Funding this from cash flows rather than significant debt is the lower-risk route for shareholders, but it also caps how fast the shift can happen.

The core economic logic is insulation from two cyclical shocks named in the story — prolonged destocking and pricing pressure in crop protection, and regulatory remediation in pharma.
Leaning on existing plants and approvals keeps capital intensity low, which should shorten the time to returns on the new lines.
With an FY26 EBITDA margin of 13.6%, the company's own framing is that double-digit margins in animal health arrive only after operating leverage, implying a margin drag in the early years.
Preferring technology partnerships and selective investment over turnover-driven acquisitions is capital-efficient, but it also means growth will be incremental rather than step-change.
The guided 14-16% revenue growth for FY27 is the first real test of whether the 2030 numbers are credible.

What to watch — Watch whether FY27 revenue growth lands in the 14-16% band and how quickly the newly commercialised personal care output at Panoli converts into reported revenue — together they will set the credibility of the 2030 targets.

The story does not establish the current revenue from these new segments, the capital being deployed, any jobs impact or how markets have responded — these are stated company targets, not delivered results.

Deep dive

Research brief · 8 facts · 10 dates · exam-ready

The brief

Context

Hikal Ltd., a maker of active ingredients and intermediates for pharmaceuticals and crop protection, has recast its growth plan around diversification, capital efficiency and higher-value chemistry. Under a "2030 strategy" drawn up after COVID-19 with consultants' advice, the next generation of leadership — Vice-Chairman and MD Sameer Hiremath and Senior President (Business Transformation) Anish Swadi — is incubating animal health and personal care businesses that can reuse existing plants, regulatory systems and multinational customer relationships. The move follows a downturn in which crop protection saw prolonged destocking and price pressure while pharma operations faced regulatory remediation. Separately, proxy advisory firm IiAS has backed Sameer Hiremath's appointment as Chairperson and Managing Director ahead of the September 23 AGM.

Key facts

Hikal aims for more than ₹400 crore revenue from Animal Health by FY30, with double-digit margins once operating leverage is achieved.
The personal care division, which recently began commercial production at Panoli, is expected to cross ₹200 crore in revenue by FY30.
Currently 60% of Hikal's revenue comes from pharma and about 40% from crop protection; Sameer Hiremath says this will change significantly over the next three to four years.
FY26 revenue was ₹1,713 crore with EBITDA of ₹232.8 crore, a margin of 13.6%.
Hikal expects revenue growth of 14-16% in FY27.
Management says no significant debt raising is needed unless a major acquisition is undertaken, which is 'currently not in the cards'.
IiAS recommended shareholders vote in favour of appointing Sameer Hiremath as Chairperson and Managing Director for five years from October 1, 2026, with the proposed remuneration.
Jai Hiremath steps down as Executive Chairperson from October 1, leaving Sameer Hiremath the sole executive representative of the Hiremath promoter faction.

Timeline

1999Sameer Hiremath's association with Hikal's board begins, a point cited by IiAS in backing his appointment.
During COVID-19Next-generation leadership reviews growth potential, capital needs and returns of the pharma and crop protection core businesses.
Post-COVID periodCrop protection hit by prolonged destocking and pricing pressure; pharma operations affected by regulatory remediation.
After the review (on consultants' advice)Company announces a 2030 strategy aimed at creating value over six to seven years rather than chasing turnover.
FY26Revenue of ₹1,713 crore and EBITDA of ₹232.8 crore (13.6% margin) reported.
RecentlyPersonal care division begins commercial production at Panoli.
September 23Hikal's Annual General Meeting, ahead of which IiAS issued its recommendation.
October 1, 2026Sameer Hiremath's proposed five-year term as Chairperson and Managing Director begins; Jai Hiremath steps down as Executive Chairperson from October 1.
FY27Revenue growth of 14-16% expected.
FY30Targets of over ₹400 crore (animal health) and above ₹200 crore (personal care) revenue.

Who has a stake

Hikal Ltd. — Seeks to reduce exposure to market cycles in pharma and crop protection by diversifying into animal health and personal care using existing assets.
Sameer Hiremath, Vice-Chairman and Managing Director — Co-led the 2030 strategy; proposed for appointment as Chairperson and Managing Director for five years from October 1, 2026.
Anish Swadi, Senior President, Business Transformation — Co-led the strategy review; argues diversification is possible 'without much investment' using the same assets and principles.
Jai Hiremath — Stepping down as Executive Chairperson from October 1, ending his executive role.
Shareholders and the Hiremath promoter faction — Vote at the September 23 AGM on the leadership appointment and remuneration; exposed to the success of the diversification plan.
Institutional Investor Advisory Services (IiAS) — Proxy adviser whose recommendation influences institutional investor voting; cites leadership continuity as the rationale.
Multinational customers — Hikal is already an approved supplier to them and plans to approach their other divisions for personal care business.

Why it matters

Hikal's pivot shows how Indian speciality chemistry firms are trying to de-risk cyclical pharma and agrochemical exposure by moving into adjacent, higher-value segments without heavy new capital expenditure. With 60% of revenue from pharma and 40% from crop protection, both hit by destocking and regulatory remediation, diversification is a test of whether existing assets and customer approvals can be monetised in new markets. The simultaneous leadership transition makes governance continuity central to executing a six-to-seven-year strategy.

UPSC angle

Prelims pointers

Hikal Ltd. is an active ingredients and intermediates company in pharmaceuticals and crop protection.
Hikal FY26: revenue ₹1,713 crore, EBITDA ₹232.8 crore, EBITDA margin 13.6%; FY27 growth guidance 14-16%.
Revenue mix: pharma 60%, crop protection about 40%.
FY30 targets: animal health over ₹400 crore; personal care above ₹200 crore.
Personal care commercial production has begun at Panoli.
IiAS (Institutional Investor Advisory Services) is a proxy advisory firm; it backed Sameer Hiremath as Chairperson and MD for five years from October 1, 2026.

Mains framing

Hikal's 2030 strategy illustrates the classic response of a mid-sized chemistry company to cyclicality: rather than chasing turnover, it is seeking capital-efficient diversification into adjacent segments — animal health and personal care — that leverage existing manufacturing assets, regulatory systems and approvals with multinational customers. The causes are structural: prolonged destocking and pricing pressure in crop protection after COVID-19, and regulatory remediation in pharmaceuticals, which together squeezed a business drawing 60% of revenue from pharma and 40% from crop protection. The implications are twofold — lower exposure to single-sector cycles and a shift in revenue mix over three to four years, but also execution risk, since animal health margins are expected to reach double digits only after operating leverage arrives and personal care has only just begun commercial production at Panoli. The stated way forward is to avoid turnover-driven acquisitions and instead prioritise technology partnerships and selective investments in existing chemistry platforms, funded from healthy cash flows without significant new debt. Governance is the other pillar: with Jai Hiremath stepping down as Executive Chairperson and IiAS backing Sameer Hiremath's five-year appointment from October 1, 2026, leadership continuity becomes a precondition for a strategy measured over six to seven years.

Key terms

Active ingredients and intermediates: The chemically active substances and part-processed inputs supplied to pharmaceutical and crop protection manufacturers — Hikal's core business.
EBITDA margin: Earnings before interest, tax, depreciation and amortisation as a share of revenue; Hikal reported 13.6% for FY26.
Destocking: Customers running down existing inventories instead of placing new orders, depressing demand and prices — seen in crop protection after COVID-19.
Regulatory remediation: Corrective action taken at plants to meet regulator requirements, which affected Hikal's pharmaceutical operations.
Operating leverage: Higher profitability as fixed costs are spread over rising volumes; Hikal expects animal health margins to turn double-digit once achieved.
IiAS: Institutional Investor Advisory Services, a proxy advisory firm that advises shareholders on how to vote on company resolutions.

Practice questions

Discuss how diversification into adjacent business lines can help Indian speciality chemical and pharmaceutical firms manage sectoral cyclicality, using Hikal's 2030 strategy as an illustration.
What role do proxy advisory firms play in corporate governance in India? Examine with reference to IiAS's recommendation on leadership appointments at Hikal.
Evaluate the trade-offs between growth through acquisitions and growth through technology partnerships and asset reuse for a mid-sized manufacturing company.

Grounded only in the source report — figures and dates are the source's, not inferred.

Next storyJ&K House Committee reports irregularities in Jal Jeevan Mission →

← All stories